西地尼布 T2500
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
25 mg | 288383-20-0 | ¥1,460.00 | 询底价 |
50 mg | 288383-20-0 | ¥1,980.00 | 询底价 |
1 mL | 288383-20-0 | ¥657.00 | 询底价 |
100 mg | 288383-20-0 | ¥3,320.00 | 询底价 |
2 mg | 288383-20-0 | ¥378.00 | 询底价 |
200 mg | 288383-20-0 | ¥4,880.00 | 询底价 |
1 mg | 288383-20-0 | ¥269.00 | 询底价 |
500 mg | 288383-20-0 | ¥7,670.00 | 询底价 |
10 mg | 288383-20-0 | ¥897.00 | 询底价 |
5 mg | 288383-20-0 | ¥589.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Cediranib
描述: Cediranib (AZD2171) 是一种可口服的高选择性VEGFR2抑制剂,对Flt1、KDR、Flt4、PDGFRα、PDGFRβ和c-Kit 的IC50值分别为小于1、小于3、5、5、36和 2nM。
细胞实验: The proliferation of the HUVEC cell line is evaluated in the presence and absence of growth factors by measuring 3H-thymidine incorporation following a 4-day incubation period. Proliferation of MG63 osteosarcoma cells is induced by PDGF-AA, which selectively activates signaling of the PDGFRα homodimer. HUVEC and MG63 osteosarcoma cells are cultured in DMEM without phenol red containing 1% charcoal stripped FCS, 2 mM glutamine, and 1% nonessential amino acids for 24 hours. Cediranib or vehicle is added with PDGF-AA ligand (50 ng/mL) and plates incubated for another 72 hours. Cellular proliferation is determined using bromodeoxyuridine ELISA. (Only for Reference)
激酶实验: Kinase inhibition: Cediranib is dissolved in DMSO at a concentration of 10 mM. All enzyme assays are run at, or just below, the respective Km for ATP (0.2 - 30 μM). The inhibitory activity of Cediranib is determined against a range of recombinant tyrosine kinases [KDR, Flt-1, Flt-4, c-Kit, PDGFRα, PDGFRβ, CSF-1R, Flt-3, FGFR1, Src, Abl, epidermal growth factor receptor (EGFR), ErbB2, Aurora A, and Aurora B] using ELISA. Selectivity versus CDK2 and CDK4 serine/threonine kinases is examined using scintillation proximity assays with a retinoblastoma substrate and [γ-sup>33P]ATP. Activity of Cediranib is compared to MAPK kinase (MEK), which shows dual specificity. It is determined using a MAPK substrate, [γ-33P]ATP, and paper capture/scintillation counting.
体外活性: Cediranib对人类移植瘤模型具有十分有效的作用且有剂量依赖性.此外,Cediranib可使人肺癌移植瘤血管衰退.Cediranib使骨骼过度生长,对卵巢中黄体的产生具有阻碍作用,并抑制依赖于血管生成的生理程序.
体内活性: 在体外,Cediranib(微摩)可直接抑制肿瘤细胞增殖。Cediranib(次纳摩)阻断细管产生,且对体内VEGF诱导的血管生成有抑制作用。Cediranib对bFGF(IC50:0.5 μM)和EGF(IC50:0.11 μM)有抑制作用。在MG63细胞系中,Cediranib抑制PDGF-AA(IC50:0.04 μM)。Cediranib抑制 Flt-1相关激酶(IC50:5 nM),还对VEGF-C和VEGF-D受体Flt-4有抑制作用(IC50<3 nM)。此外,Cediranib对c-Kit(IC50:2 nM)和PDGFR-β(IC50:5 nM)酪氨酸激酶有抑制作用。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 83 mg/mL (184.2 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字: Platelet-derived growth factor receptor | Vascular endothelial growth factor receptor | PDGFR | inhibit | VEGFR | Cediranib | NSC732208 | AZD 2171 | NSC 732208 | Autophagy | AZD-2171 | Inhibitor
相关产品: VEGFR-2/c-Met-IN-1 | BMS-605541 | Tesevatinib | Bucillamine | NVP-BAW2881 | EOC317 | Sitravatinib | Nintedanib | Sunitinib-d10 | Vomifoliol
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Highly Selective Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Approved Drug Library
西地尼布 T2500信息由TargetMol中国为您提供,如您想了解更多关于西地尼布 T2500报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途